329 related articles for article (PubMed ID: 19752345)
21. BAALC and ERG expression in acute myeloid leukemia with normal karyotype: impact on prognosis.
Eid MA; Attia M; Abdou S; El-Shazly SF; Elahwal L; Farrag W; Mahmoud L
Int J Lab Hematol; 2010 Apr; 32(2):197-205. PubMed ID: 19555438
[TBL] [Abstract][Full Text] [Related]
22. BAALC expression and FLT3 internal tandem duplication mutations in acute myeloid leukemia patients with normal cytogenetics: prognostic implications.
Baldus CD; Thiede C; Soucek S; Bloomfield CD; Thiel E; Ehninger G
J Clin Oncol; 2006 Feb; 24(5):790-7. PubMed ID: 16418499
[TBL] [Abstract][Full Text] [Related]
23. High IL2RA mRNA expression is an independent adverse prognostic biomarker in core binding factor and intermediate-risk acute myeloid leukemia.
Du W; He J; Zhou W; Shu S; Li J; Liu W; Deng Y; Lu C; Lin S; Ma Y; He Y; Zheng J; Zhu J; Bai L; Li X; Yao J; Hu D; Gu S; Li H; Guo A; Huang S; Feng X; Hu D
J Transl Med; 2019 Jun; 17(1):191. PubMed ID: 31171000
[TBL] [Abstract][Full Text] [Related]
24. Low ERG and BAALC expression identifies a new subgroup of adult acute T-lymphoblastic leukemia with a highly favorable outcome.
Baldus CD; Martus P; Burmeister T; Schwartz S; Gökbuget N; Bloomfield CD; Hoelzer D; Thiel E; Hofmann WK
J Clin Oncol; 2007 Aug; 25(24):3739-45. PubMed ID: 17646667
[TBL] [Abstract][Full Text] [Related]
25. Over expression of brain and acute leukemia, cytoplasmic and ETS-related gene is associated with poor outcome in acute myeloid leukemia.
Hasan SK; Patkar NV; Rajamanickam D; Gokarn A; Lucena-Araujo AR; Tembhare P; Bagal B; Kadam Amare P; Jain H; Gujral S; Sengar M; Subramanian PG; Khattry N
Hematol Oncol; 2020 Dec; 38(5):808-816. PubMed ID: 32893896
[TBL] [Abstract][Full Text] [Related]
26. Prognostic significance of expression levels of stem cell regulators MSI2 and NUMB in acute myeloid leukemia.
Thol F; Winschel C; Sonntag AK; Damm F; Wagner K; Chaturvedi A; Göhring G; Schlegelberger B; Lübbert M; Fiedler W; Kirchner H; Krauter J; Ganser A; Heuser M
Ann Hematol; 2013 Mar; 92(3):315-23. PubMed ID: 23233047
[TBL] [Abstract][Full Text] [Related]
27. BAALC is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML).
Santamaría C; Chillón MC; García-Sanz R; Pérez C; Caballero MD; Mateos MV; Ramos F; de Coca AG; Alonso JM; Giraldo P; Bernal T; Queizán JA; Rodríguez JN; Puig N; Balanzategui A; Sarasquete ME; Alcoceba M; Díaz-Mediavilla J; San Miguel J; González M
Ann Hematol; 2010 May; 89(5):453-8. PubMed ID: 19943049
[TBL] [Abstract][Full Text] [Related]
28. The Prognostic Relevance of BAALC and ERG Expression Levels in Cytogenetically Normal Pediatric Acute Myeloid Leukemia.
Aref S; Al Khodary T; Zeed TA; El Sadiek A; El Menshawy N; Al Ashery R
Indian J Hematol Blood Transfus; 2015 Mar; 31(1):21-8. PubMed ID: 25548440
[TBL] [Abstract][Full Text] [Related]
29. Implication of higher BAALC expression in combination with other gene mutations in adult cytogenetically normal acute myeloid leukemia.
Yoon JH; Kim HJ; Shin SH; Yahng SA; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW; Lim JH
Leuk Lymphoma; 2014 Jan; 55(1):110-20. PubMed ID: 23647058
[TBL] [Abstract][Full Text] [Related]
30. ID1 expression associates with other molecular markers and is not an independent prognostic factor in cytogenetically normal acute myeloid leukaemia.
Damm F; Wagner K; Görlich K; Morgan M; Thol F; Yun H; Delwel R; Valk PJM; Löwenberg B; Heuser M; Ganser A; Krauter J
Br J Haematol; 2012 Jul; 158(2):208-215. PubMed ID: 22568493
[TBL] [Abstract][Full Text] [Related]
31. Prognostic importance of histone methyltransferase MLL5 expression in acute myeloid leukemia.
Damm F; Oberacker T; Thol F; Surdziel E; Wagner K; Chaturvedi A; Morgan M; Bomm K; Göhring G; Lübbert M; Kanz L; Fiedler W; Schlegelberger B; Heil G; Schlenk RF; Döhner K; Döhner H; Krauter J; Ganser A; Heuser M
J Clin Oncol; 2011 Feb; 29(6):682-9. PubMed ID: 21205756
[TBL] [Abstract][Full Text] [Related]
32. CD34 expression predicts an adverse outcome in patients with NPM1-positive acute myeloid leukemia.
Dang H; Chen Y; Kamel-Reid S; Brandwein J; Chang H
Hum Pathol; 2013 Oct; 44(10):2038-46. PubMed ID: 23701943
[TBL] [Abstract][Full Text] [Related]
33. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations.
Green CL; Koo KK; Hills RK; Burnett AK; Linch DC; Gale RE
J Clin Oncol; 2010 Jun; 28(16):2739-47. PubMed ID: 20439648
[TBL] [Abstract][Full Text] [Related]
34. Integrative prognostic risk score in acute myeloid leukemia with normal karyotype.
Damm F; Heuser M; Morgan M; Wagner K; Görlich K; Grosshennig A; Hamwi I; Thol F; Surdziel E; Fiedler W; Lübbert M; Kanz L; Reuter C; Heil G; Delwel R; Löwenberg B; Valk PJ; Krauter J; Ganser A
Blood; 2011 Apr; 117(17):4561-8. PubMed ID: 21372155
[TBL] [Abstract][Full Text] [Related]
35. Meningioma 1 (MN1) expression: refined risk stratification in acute myeloid leukemia with normal cytogenetics (CN-AML).
Aref S; Ibrahim L; Morkes H; Azmy E; Ebrahim M
Hematology; 2013 Sep; 18(5):277-83. PubMed ID: 23394438
[TBL] [Abstract][Full Text] [Related]
36. RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.
Mendler JH; Maharry K; Radmacher MD; Mrózek K; Becker H; Metzeler KH; Schwind S; Whitman SP; Khalife J; Kohlschmidt J; Nicolet D; Powell BL; Carter TH; Wetzler M; Moore JO; Kolitz JE; Baer MR; Carroll AJ; Larson RA; Caligiuri MA; Marcucci G; Bloomfield CD
J Clin Oncol; 2012 Sep; 30(25):3109-18. PubMed ID: 22753902
[TBL] [Abstract][Full Text] [Related]
37. GAS6 expression identifies high-risk adult AML patients: potential implications for therapy.
Whitman SP; Kohlschmidt J; Maharry K; Volinia S; Mrózek K; Nicolet D; Schwind S; Becker H; Metzeler KH; Mendler JH; Eisfeld AK; Carroll AJ; Powell BL; Carter TH; Baer MR; Kolitz JE; Park IK; Stone RM; Caligiuri MA; Marcucci G; Bloomfield CD
Leukemia; 2014 Jun; 28(6):1252-1258. PubMed ID: 24326683
[TBL] [Abstract][Full Text] [Related]
38. Relation of BAALC and ERG Gene Expression with Overall Survival in Acute Myeloid Leukemia Cases.
Rashed RA; Kadry DY; El Taweel M; Abd El Wahab N; Abd El Hameed T
Asian Pac J Cancer Prev; 2015; 16(17):7875-82. PubMed ID: 26625814
[TBL] [Abstract][Full Text] [Related]
39. A stem cell-like gene expression signature associates with inferior outcomes and a distinct microRNA expression profile in adults with primary cytogenetically normal acute myeloid leukemia.
Metzeler KH; Maharry K; Kohlschmidt J; Volinia S; Mrózek K; Becker H; Nicolet D; Whitman SP; Mendler JH; Schwind S; Eisfeld AK; Wu YZ; Powell BL; Carter TH; Wetzler M; Kolitz JE; Baer MR; Carroll AJ; Stone RM; Caligiuri MA; Marcucci G; Bloomfield CD
Leukemia; 2013 Oct; 27(10):2023-31. PubMed ID: 23765227
[TBL] [Abstract][Full Text] [Related]
40. The expression level of BAALC-associated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute myeloid leukemia.
Díaz-Beyá M; Brunet S; Nomdedéu J; Cordeiro A; Tormo M; Escoda L; Ribera JM; Arnan M; Heras I; Gallardo D; Bargay J; Queipo de Llano MP; Salamero O; Martí JM; Sampol A; Pedro C; Hoyos M; Pratcorona M; Castellano JJ; Nomdedeu M; Risueño RM; Sierra J; Monzó M; Navarro A; Esteve J
Blood Cancer J; 2015 Oct; 5(10):e352. PubMed ID: 26430723
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
